These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11365848)

  • 21. Rebuilding the immune system.
    Averitt D
    WORLD; 1999 Apr; (No 96):1-2. PubMed ID: 11366944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
    Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
    Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial.
    De Rossi A; Walker AS; Klein N; De Forni D; King D; Gibb DM
    J Infect Dis; 2002 Aug; 186(3):312-20. PubMed ID: 12134227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline thymic volume is a predictor for CD4 T cell repopulation in adult HIV-infected patients under highly active antiretroviral therapy.
    de la Rosa R; Leal M; Rubio A; Martinez-Moya M; Delgado J; Ruíz-Mateos E; Merchante E; Sánchez-Quijano A; Eduordo L;
    Antivir Ther; 2002 Sep; 7(3):159-63. PubMed ID: 12487382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune control.
    Fornataro K; Jefferys R
    Body Posit; 1999 Mar; 12(3):9-12. PubMed ID: 11366299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-2 (IL-2): a path toward functional eradication?
    Proj Inf Perspect; 1998 Dec; (26):20-1. PubMed ID: 11366494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why is IL-2 being considered?
    TreatmentUpdate; 1999 Mar; 11(2):2-3. PubMed ID: 11366775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone in T-lymphocyte thymic and postthymic development: a study in HIV-infected children.
    Vigano A; Saresella M; Trabattoni D; Giacomet V; di Natale B; Merlo M; Venuto A; Villa ML; Vanzulli S; Ferrante P; Clerici M
    J Pediatr; 2004 Oct; 145(4):542-8. PubMed ID: 15480382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of niche aging on thymic regeneration and immune reconstitution.
    Chidgey A; Dudakov J; Seach N; Boyd R
    Semin Immunol; 2007 Oct; 19(5):331-40. PubMed ID: 18024073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Porcine thymic grafts protect human thymocytes from HIV-1-induced destruction.
    Hongo D; Hadidi S; Damrauer S; Garrigue V; Kraft D; Sachs DH; Nikolic B; Sykes M
    J Infect Dis; 2007 Sep; 196(6):900-10. PubMed ID: 17703422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies.
    Angel JB
    AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.
    Marziali M; De Santis W; Carello R; Leti W; Esposito A; Isgrò A; Fimiani C; Sirianni MC; Mezzaroma I; Aiuti F
    AIDS; 2006 Oct; 20(16):2033-41. PubMed ID: 17053349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-based therapy for HIV.
    Engle J
    Nurs Clin North Am; 1996 Mar; 31(1):15-23. PubMed ID: 8604377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-2 plus HAART reduces HIV in immune system "hiding places".
    WORLD; 1998 Dec; (No 92):7. PubMed ID: 11365976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on immune-based therapies.
    PI Perspect; 1996 Nov; (No 20):10-4. PubMed ID: 11363965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic humoral factor THF-gamma2.
    Ben-Efraim S; Keisari Y; Ophir R; Pecht M; Trainin N; Burstein Y
    Crit Rev Immunol; 1999; 19(4):261-84. PubMed ID: 10530429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.